Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7109676 | 0.90 | LTA4H (0.48) | LTA4HHDAC6HDAC1ADORA2APDE4B | |
| SCHEMBL11066170 | 0.82 | ADORA2A (0.50) | LTA4HHDAC6HDAC1ADORA2APDE4B | |
| SCHEMBL5635371 | 0.81 | LTA4H (0.49) | LTA4HHDAC6HDAC1ADORA2APDE4B | |
| SCHEMBL21591536 | 0.79 | LTA4H (0.48) | LTA4HHDAC6HDAC1ADORA2APDE4B | |
| SCHEMBL13587965 | 0.78 | LTA4H (0.56) | LTA4HHDAC6HDAC1ADORA2APDE4B | |
| SCHEMBL31590059 | 0.78 | LTA4H (0.47) | LTA4HHDAC6HDAC1ADORA2APDE4B | |
| SCHEMBL48336 | 0.78 | ADORA2A (0.47) | LTA4HHDAC6HDAC1ADORA2A | |
| SCHEMBL13044929 | 0.74 | HDAC6 (0.47) | LTA4HHDAC6HDAC1ADORA2APDE4D | |
| SCHEMBL338773 | 0.72 | HDAC6 (0.52) | LTA4HHDAC6HDAC1TDP1 | |
| SCHEMBL3671306 | 0.71 | FDPS (0.51) | LTA4HHDAC6HDAC1ADORA2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0831812-B1 | METHODS AND COMPOSITIONS FOR STIMULATING NEURITE GROWTH | VERTEX PHARMA (US) | 2005-12-07 | — | — | EP | claimed |
| EP-0584223-B1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMA (US) | 1999-08-11 | — | — | EP | claimed |
| US-5620971-A | Biologically active acylated amino acid derivatives | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1997-04-15 | — | — | US | claimed |
| EP-0584223-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1994-03-02 | — | — | EP | claimed |
| WO-1992019593-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1992-11-12 | — | — | WO | claimed |
| US-7825136-B2 | Potentiators of antibacterial activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090291964-A1 | Potentiators of Antibacterial Activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-11-26 | — | — | US | disclosed |
| US-20050090482-A1 | mixture of antibiotics, carriers and activators such as (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester, used for treatment of bacterial infection in mammals | VERTEX PHARMACEUTICALS INCORPORATED | 2005-04-28 | — | — | US | disclosed |
| US-6326387-B1 | NEUROTROPIC COMPOUND | VERTEX PHARMACEUTICALS INCORPORATED | 2001-12-04 | — | — | US | disclosed |
| EP-1117371-A2 | METHOD OF TREATING HAIR LOSS USING KETOAMIDES | The Procter & Gamble Company (US) | 2001-07-25 | — | — | EP | disclosed |
| EP-1117372-A2 | METHOD OF TREATING HAIR LOSS USING SULFONAMIDES | THE PROCTER & GAMBLE COMPANY (US) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018361-A2 | METHOD OF TREATING HAIR LOSS USING SULFONAMIDES | THE PROCTER & GAMBLE COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000018358-A2 | METHOD OF TREATING HAIR LOSS USING KETOAMIDES | THE PROCTER & GAMBLE COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291964-A1 | Potentiators of Antibacterial Activity | SLC11A2, MPO, ABCB11 | LTA4H 1214/4885HDAC6 1681/4885HDAC1 1520/4885 |
| US-20050090482-A1 | mixture of antibiotics, carriers and activators such as (S)-1-((3,4,5-Trimethoxyphenyl)-methyl-carbamoyl)-piperidine-2-carboxylic acid 4-pyridin-3-yl-1-(3-pyridin-3-yl-propyl)-butyl ester, used for treatment of bacterial infection in mammals | TLR1, ABCB11, SLC7A1 | LTA4H 1084/4885HDAC6 702/4885HDAC1 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.